 So with that, we come to a close to another amazing summit. And as we say every year, the summit every year gets better and better. And I can't imagine that we've ever had a more esteemed group of panelists and moderators, fireside chats than we did this year. And so thank you all. I'd like to share some of my learnings and tell a story. So I captured five learnings over the course of the day. And I think that you'll appreciate these. The first is that, and I cringe saying this, having grown up in Merck, but Pfizer is the coolest biotech company in the industry. The second is Delios Papadopoulos is a gourmet chef, but the jury is still out on Elio Sahuni. The third is a truism, which is that Sam Waxall cannot be contained. The fourth, I love this, is sometimes you get back from the FDA would make Alan Greenstein. That's one from you, Chris V. Backer. And then you get another, which is the last one, is that if you work in pharma and want to be loved by a dog, and Chris, I have two dogs, so I'm pining for love. The second, more seriously, is a story that takes me back to Majid Jafar, one of our panelists in the rare diseases panel. I met Majid in 2016, January of 2016, in Davos at the World Economic Forum. My first and so far only time at that incredible setting, and it's like speed-nating. People reach out and try to meet with you. And so here was this brilliant oil magnet from UAE who wanted to meet with me. And so we sat down, and he started telling me the story of his daughter that he mentioned today, Alia, who had just been diagnosed with this very rare genetic condition called CDKL5 deficiency, of which there were only tens or maybe hundreds of patients in the world. We had a great conversation, and we've become friends ever since. And the story is that what Majid has done with his wife, Lynn, over the past half decade defines innovation in our industry. They were inspired, saddened, and then inspired by a disease that their daughter had to understand this disease and to find a cure. And so a brilliant engineer, businessman who had inherited a family business, spent half of his time running that business and the other half of his time trying to seek the cure. And what he's done in terms of rallying the world, academics, and industry together in terms of enhancing diagnosis. So today, the disease that we thought was tens or hundreds is now thousands or tens of thousands. And the great progress that he's made in advancing innovation is really an allegory of the world we live in. And then separately, and it brings me to something that we didn't touch on at the level, perhaps that we needed to today, is diversity, equity, and inclusion. And I'll tell a story which I apologize to Majid in advance for telling this, but he started it. And his wife, Lynn, who's a brilliant individual in and of herself is of course not well versed in healthcare, but Majid had started to get to know what healthcare was about. And he told the story explaining what was wrong with Alia, which is that she had a letter missing in one of her genes. And Lynn, you know, perhaps naively said, well, why can't we just replace the letter? And she got mansplained. And then she got mansplained by Majid, she said, well, no, you can't do that. Well, in the end, you actually can do that. You can. And that in the fact may be the cure to diseases like CDKL5 deficiency. And it takes me to this idea of diversity, equity, and inclusion, because great ideas, such as the idea that Lynn have can come from anywhere, anywhere. That's why we need to emphasize diversity and inclusion in everything that we do. And the last comment I'll make relates then to this organization, which if you look back and you look back at our website, you look back at the meetings that we've had up until last year, we've not been diverse. We've been men standing up here talking with other men. Last year we started to change at maybe even more strides, but I have to, and I have to thank you Karun for really standing up as well as the advisory board for taking hold of something that perhaps we should have even before we did. But we're on a learning curve as much as the world is and we're committed in this organization to ensure that when you sign in next year, the people you see on the screen represent the diversity of the populations that we live in. My last comment, then I'll hand it over to Karun or thanks in three buckets. The first I'd like to thank the incredible group of participants, our moderators and our panelists. It was just really remarkable. And the preparation that all of you made and going into today showed in spades. Second, I'd like to thank Karun. Karun is, as Martin I said, once you're in two years in row, you're in for life. Karun is just a force of nature and every year it's Karun's will that makes this happen. And then thirdly and most importantly, I'd like to thank all of you. If you're sitting here over the course of today engaging in this discussion, you have an interest in healthcare. Now, whether you're an entrepreneur, whether you're a VC, whether you're in biotech, whether you're a physician, whether you're a scientist, whoever you are, you may have different motivations, but we all share a common motivation and that's our interest in ensuring that lives can be better for patients around the world. And that's our theme from end of one to end of a billion. So with that said, Karun, I will thank you once again and hand the mic to you. Copy Andy, I think, what have you said? Thanks for everybody except myself because I can't thank myself. So thanks a lot, we have a, I think if we can go for the full screen, you can see there are a couple of colleagues in the gallery view, you can see all of them, they are there. So thanks here, you know, being with us. But before that, you know, many of you don't know that, you know, background. We had this, our own vendor, what should I mean, see just we got them two weeks back and all these colleagues are joining in from Delhi, Hyderabad and from Jaipur. Different teams are there. I think they did a reasonably good job. You're not able to watch it, but I was on top of them since morning, you know, today, of course, before that also. But I think there's a good learning and they're doing a great job in terms of execution remotely and they've been very flexible in terms of, you know, doing your tech check and everything. Everybody had a scheduling problem and everything, but they were very, you know, like till about two o'clock in the night, they were able to do that. So if you're around, you raise your hands from your, you know, what should I mean, see where are you? And yeah, Mike is there, Pratik is there. Where is Pratik? Do we have more? Okay, Pratik is on the next page. Let me see that. Yeah, Pratik is there. I see him, all right. And Dr. Priyanka is there. So thank you so much. I think you had a good job. Hopefully we don't have to do this work next year. We'll do it in person, but if at all we do it, we will get you in. Definitely, I recommend you to all of you. So thank you so much. Now, coming back, I think I've done a lot of work. So I need some rest. So tell us, take over. Well, to you, Karun, and our dear Supreme Commander, Andy, truly, truly congratulations. I know I believe this strongly. This was the best ever. Even though it wasn't face-to-face. And I should say this. The last time I attended a whole conference from beginning to end, maybe 30 years ago, but I was given the monitor all day-to-day. Great job. Every panel, fantastic. So congratulations. Elias, you have to be short because you overstepped already by 10 minutes. Great job, Elias. Thank you. Go ahead. You're talking about me? Yes, yes, I'm talking to you. Well, I agree with Stelios and I agree with Andy. I think you're a force of nature. I've learned a long time ago that never turn down Karun. It's a lot harder to turn him down than to just accept right away and say, okay, I surrender. And so I surrendered to your requests and all of us did and you achieved an extraordinary result. As always, it's fun to work with you. I think some people had trouble with the background and I did and your team helped me fix it so I'm on your background. But frankly, I think the conference really addressed leading-edge issues and that's what I like about the way this comes together. Andy, as a moderator, I promise once I perfect my couscous cooking, I will invite you. So I'll try to match Stelios in his... We're a good group, we're a group of friends. This is what I like, the fact that we have an open dialogue and I think you're able to attract this as Andy said, the more diverse, more inclusive participant group and moderators as well as contributors, which I think should really be, in my view, an example of what can be done virtually but hopefully next year in person. So that, I'll stop, Karun, and thank you again. Thank you, Les. What do I do? I do the best instructions of my commander-in-chief. So Andy directs me and I go after you or anybody he directs. So you know who's behind me all the time. I was for it. You are a very persistent, resilient manager of many, many, many other people. And frankly, we did it. We brought who you wanted and we organized the things as you wanted. And as I said, guys, don't resist Karun. There's no reason for that. I'm sure all of you agree. Karun will not let you go until you say yes. So just say yes and go. Right? So I have to, Karun, you and Andy were unbelievable today. You're out of time. No, it's okay. I have to tell you, Karun, you are a force of nature. I've been dealing with you on lots of things and it's unbelievable. Andy, you were a superstar today. And all of my, you know, what's really nice is what Elias said about us being friends because it's really fun to adjust and to synergize and to do all sorts of things with people that you respect, that you care about and that are fun as colleagues in an important world. So thank you, Karun. And thank you, Andy. Yeah, appreciate it. So, Lena, you're in Spain and good to have you. You didn't see and I remembered her like, you know, she let bring them and I said, let me find out. You know, she was pretty active on LinkedIn. And here she is. So thanks a lot for being with us. I hope really enjoying this, you know, the weather in Spain. I am and thank you so much for inviting me. You know, even if I live in Spain, I still have all my projects and all my entrepreneurial projects in the States. And it's very exciting to be here and to be still connected to the pharma world, even if I left Novartis so many years. But now, you know, the interest for me here is to not only participate as a scientist, but also as a patient. And that has been my mission right now, which is to push the rare disease understanding and development in biomedical pharma as well, you know, for this community of rare disease, especially for adult rare diseases that have been misagnosed for a long time. So thank you for giving me the chance to continue being linked to this community. Heron Reeves, very, you know, die hard supporter, like, you know, typically, you know, we have a, you know, registration fee. So she's one of those startups. She actually paid for it. And she wanted to pay a registration fee a couple of years back over there. And that's how we connected. And you think I am persistent. She is, I think, two X or three X what I am. And even before this, like, you know, she knows everybody, whether it's Martin McKay or Stelios and others. And it's, you know, I liked it. The email comes to Andy from one of his colleagues that, hey, Karen is going to be participating and she's my ex-colleague. And Andy thought to me that we should have her. I said, look, she's already coming for many, many years now, you know, and pretty supportive. So Karen, welcome back. Thank you so much. May I just say one thing to the, all the former colleagues of Pfizer and everybody else developing drugs. It's really an example of to save one person is to save the whole world. Can we elaborate? So, Karen, from the Talmud, from the Talmud. We can have one on one later. David, thanks for being here. I know it's a busy day for you, David Meeker. Yeah, no, thanks, Karen. So I didn't catch all the conference, but I will say, I think what others have said, there's a tremendous value to having people on panels who have been there multiple times. I think much of our industry and the world we live in are people who pass through and they're sort of 30, 45 minutes talking to somebody or with people you may or may not know well, but there's a depth to this, which comes from having worked together over years. And I think it brings a lot to this conference. Thanks, I really appreciate, you know, you've been, since Gensheim days, you know, been part of this, you know, platform. That's great. And John Reid, you know, I hope you are feeling comfortable because Martin said, like your rookie, you know, whatever it was, first time. And when we spoke a couple of days back, I said, you don't know much about the platform, but now hopefully you're getting to know a little bit. And we are confident. Thank you. I really enjoyed my rookie debut and getting into the first game here. Didn't score any touchdowns or anything, but it was fun to be on the playing field. Really enjoyed the opportunity to dialogue. I think one of the benefits of a Congress like this, even, you know, even when it's done virtually is that, you know, it helps you realize what a small world it is in which we operate in the biomedical research community. You know, how much we're all driven by the same core purpose of helping patients and elevating the standard of care. And I think Congress is like this, you know, can be a platform for future collaboration, you know, because it's really all about collaboration and creating the synergies from complementary expertise and resources. So I think it's, you know, congratulations, Karun, because I think you're a catalyst for collaboration. Thanks a lot being here and I hope, you know, probably you'll find some more time next year. We don't have to chase you for your appointments. So you'll keep clear your calendar and you know, I know you're busy, but I appreciate you, you're spending time with us. Karun. Thank you. Karun, I can stand here. Did I pronounce it correctly? Yes, you did. Thank you so much for the invite. I caught the last panel. It's so inspiring to hear from the leaders who are, you know, really pushing forward the frontiers of what farmers going to look like in the future. And for those of us that are in smaller companies, and I'll just echo what John said, I think by working together on a lot of the issues, not just drug discovery and drug development, but how biopharma is seen by the world, how we can help the world. I think I understood Karun's comment there about, you know, if we help one patient, that's part of this huge journey to helping all patients. So I'm just very excited to be here and really appreciate you inviting me and I look forward to participating next year. And congrats, really great. No, thanks a lot. Really appreciate Rajiv call from California or Bostonian right now in California. Well, I had to make him wear a jacket today. So yesterday, we were chit-chatting. I'm part of your fan club and so, you know, I'm gonna just add to the enthusiastic support from everyone. So thank you for that. You know, I have a kid from Bombay with a dream to come to America. So it's very inspirational. Thanks to you to connect some of these dots. So... I'm going to say something to your dad. I'd like to do something for Sam. I know where Sam hangs out. I know how to catch him in his favorite location in New York City. We ran into each other the other day and we had fun. Yes. Well, I think Sam's there every evening at about 730 p.m. because I think this is the second time I'm gonna do that. Anyway. Well, all that means is that you and I both went to the same place on those two days. The data management people will tell you that. Awesome. Well, you know, I will also just say, Andy, you're so brilliant and eloquent. Your comment I think was the one that I'm taking away from the whole great conference, the way you said that, you know, today we're making the drugs, but in the future, it's going to be the data-driven information companies and the companies, the 10 largest biopharma companies in the next decade through decades are gonna be very different from what we've seen today. And that really resonates with me and I think that's a very visionary statement. So thanks for everything. Yeah, thanks Rajiv. And still you need to raise this toast, which is pending for last two and a half years. You didn't raise the toast that day. So we'll have it hopefully maybe in November, December when things really improve and we can have it for all the people in the group. Anita. Well, Karun, thank you very much for having me be a part of this extraordinary group of people. I'm obviously the rookie here, but it's just very fortunate. And when I was doing work related to India, Karun was instrumental in making so many introductions and I'll be forever grateful. And I think ever since I've just been part of this group. And so thank you all for having me. I think this is an industry that has a huge impact on people's lives everywhere in the world irrespective of where you are and what socioeconomic class you belong to and the fact that we're all able to contribute in that despite being part of a for-profit sort of organization as most of us are. I think it's a privilege that I'm very glad to be a part of. Well, pleasure having you and I'm glad your colleague Vivek could join. So between two of you, I think Roy was well-represented over here. Daphne, you did a fantastic job. We have been, you know, chatting, but I think you had a lot of depth the way you did it. So congratulations to you, like what you did. So like to hear not about me, we can say something else. Yeah, thank you. And I wasn't sure if you were talking to me or the other Daphne, which is really unusual. There's hardly ever a situation where there's another Daphne. So it was nice to see. Well, I just say that- Sorry, you missed one thing, Daphne. They actually, Mathai is not here. He won't. When the lower third came, it was your name. It was a mistake at the time because you couldn't watch because you were on stage. You had put Daphne Collar at the time. So quickly they had to replace it and Mathai caught it because I couldn't see that because I was on the stage. So he said, they put the wrong one. I said, it's Daphne, yeah, but it's Daphne Collar. So they corrected that data wrong within a few seconds. Yeah, so what I would say is when you first asked me to be part of this conference a year ago, I thought it was just a conference. I didn't realize it was like a community or I don't know if you want to call it a salon, but these calls that we have every few months, it's much more than a conference. It really is. We get together and I hear, I get to hear from some of the great colleagues here about where the industry is headed and all of the discussion. I actually think that part of it for me has been really rewarding and I really appreciate being part of this community and I really enjoyed myself today. So thank you. I thought it was a great conference and I just complimented everyone who participated. It was wonderful. Thank you. I really appreciate your advice and your insights. So thanks a lot over there. We really appreciate what you're doing and in terms of your professional work. So really thanks a lot, I appreciate over there. Bill Chin, you managed very well, Janet. I think it was a real smooth conversation and I got her text messages from her staff. So she's very happy. She wants the copy of the video to be watched. Well, I have just a few thoughts. I'm laughing because we just talked, Andy talked about dogs and one of my dogs just jumped up and licked me. So this is how it goes. So I guess I would have to agree with everyone. I've been involved with this summit for a number of years now and I really think this was the best. And I think there's just so much community, collaborative spirit enough to continue to sort of provide hope that this industry will continue to be fantastic. I just wanna say something about John Reed as a rookie. He did ask a very good question. Appreciate that. And then finally, I wanna say something about you, Karun. I've been trying to fathom why all of us seem to be at your sort of beck and colt. You know, we say Andy's the supreme commander but I say you're the supreme supreme commander. Andy, you agree with that? You're nodding. And you know, what it is, Karun, is it's not just devotion. You really care about all this and you care, you know, I always thought you just care because that's your job, you know, as head of the Chamber of Commerce, but you care and I've known you through, you know, your personal involvement with the illness in the family. And I just must say that that just touches me so much in terms of how you continue to conduct yourself. I think some of us know about your recent loss and, you know, maybe you don't wanna share that but you have a recent loss of your mom and, you know, this is through all this planning and it's just amazing. So I have a tear in my eye and I, you know, I salute you even more for what you do and what you do for all of us. So thank you. Really, thanks. And, you know, like you said, something about the, you know, mother, I lost my sister also. I lost my sister two weeks back. Oh, you lost your sister, that's right. Yeah. I was just 69 within like 45 days. But, you know, what all of you do in the industry and academics in the research, I think it's so critical, so important. And this is what really motivates you, charges you, energizes you. Because when you see the pain, when you see the suffering, I didn't talk much in the morning about the deli COVID. I was there for a month in April at the peak. And that too, I was, you know, with my mom for about three weeks, you know, two weeks in the ICU and I could see the patients coming in there. It was horrible. Like, you know, the worst thing is when you see that pain and you cannot do anything, you feel helpless because like the hospital can take maybe like Dr. Tren was in the morning from Medanta. Maybe he can take 700, you know, people in his, but he has got 7,000 people turning up. What he can do, we can't help anybody over there. So the death, the misery and like it was pretty terrible. And that's why I think what we do today, it gives you some kind of satisfaction. It's not that, you know, we all met today and some, you know, magic vaccine or a pill will come at the end of the day. But I think all of you have actually seeded ideas, strategies, selflessly, like, you know, whatever is public domain and people will take it forward. Like, you know, results won't come today, but somebody said about the deals, deals are happening. You know, people, some, they talk about it. They're in public domain. Some are not, but when you have the right set of people in the room, things happen. Good ideas emerge over there. But thanks, I really appreciate over there. So Dhaval, you didn't put your virtual background today, I was told. Because I didn't get one, Karun. You had to buy it, you didn't pay for it, or you know, all these sponsors get it. Oh, okay, well, I didn't pay for it. Sorry about that. Hey, listen, what a dynamic day. I have to say that the way people communicated with each other got along, the panels were really free flowing. And I liked a lot of the back and forth and Andy, of course, always masterful. One of the things that struck me the most today was a little bit of what Janet Woodcock said. I'm not sure how many people picked up on it, but she called out the community trial where some of the groups got together and tried to do something together. For me, the leaders of that group are right here at this table. Andy was a big driver of that, as well as Dave Reese, who with Amgen really sponsored that community trial. I'm lucky to be at the table with these guys because then I was able to work with them to do something, you know, just join them. But it wouldn't have happened without this. This was one of those rare times that I think we as sometimes competitors in industry actually get together and really be friends and do form those collaborations. So I would say that that kind of collaboration is an example of what you have accomplished. Thanks a lot. Thank you. Yeah, first of all, it was a great day. Each panel was really exciting and there were so many insights that came out of each of them. And after coming to this for quite a few years now, I'm really excited about the community and I'm really excited to get together in person later this year or next year as we start to get back to normalcy. And it's really a testament to the effort of a lot of the people that come together in this community that we were able to come up with a vaccine as well as therapeutics and in such a short time, it just validates everything that we do on a daily basis. And Karun, thank you for pulling all of this together. And Andy, it was a great session and thank you for your coaching yesterday or day before whenever we talked. It's just these little things that matter a lot. By the way, that PDF file, it went to everybody. Like it was so like, you know. It was fantastic. Yeah, very simple things, but it helps everybody, you know, basically. Sam, this is your official time to speak. Wow. Well, I appreciate that. I've already said everything I wanted to say. You know, it is, by the way, I don't believe that Andy really meant that he was going to be the CEO of a company only doing work in med tech and data management. He, you know, was sort of being nice. He's still gonna be the head of research of drug discovery. I'm a big believer in drug discovery. And I only believe that data management works when you've got a lot of data and we still haven't gotten all the data we need. So it's a marriage and that marriage will move forward quite nicely. Karun, you know, I spoke to you right after you got back from India and had spent that time in the ICU with your mom and then brought her home. I told you then you were a super son and it's rare to find people that are that committed to family and are that committed to what we do here and are that committed to lots of things. And that's why you're so unbelievable. I must say that you've had a hard year and yet at the same time you've been doing everything you can to make this move forward. It's very impressive. And Andy, thank you for just spending the time. I know a lot of my colleagues out there, you know, from John to Stelios to Chris and all of you don't have a lot of time and we all make time for this. I think it's great. I think it actually serves a purpose. It makes our brains move in the right direction. Sometimes they just move and they don't always move in ways that are as useful as this makes them. So thank you. You were unbelievable. Thank both of you. Thanks, Sam. I lost my mother on 9th May, early morning, 2.30 in Delhi and 8th May, I think it was about 11.30 in the night, me, Sam and Dr. Trehin were on a Zoom call at that time. Working on something else, which you know, Sam felt that is important to save lives in India. And this was about, I think, 11.312, we finished that call at 12.30 and after two hours, I lost her over there. And if you look at this screen right now, we have colleagues from different faiths over there. So she, we are all Hindu by faith. So I wanted to celebrate her life on that 13 day. So I had a multi-faith service. So I had a Hindu priest, a Sikh priest. I had a Imam, I had, you know, Reverend Bishop from Delhi was there. And then I wanted to get a rabbi, you know. So I didn't know at that time that, you know, Andy could do the same that Kudish, right? The prayer he told me. So of course, you know, Rajiv has bumped into, you know, Sam in New York two times in the same, some exotic or exciting place. So I called Sam, Sam, I needed a rabbi. So here it was Sam. So he, I think it was Neva Steve, right? So he called me and said, Sam, what's the way to do prayers for your mom? And, you know, then we had this, you know, all five, you know, prayer religious prayers for there. He logged in from New York and then Bishop was from Bangalore and Imam from Mumbai. So this is the other side of Sam. I don't know how much religious he is, but he knows the right people. So when you need a rabbi to do anything, whether it's your wedding or funeral, you can, you know, besides doing a deal making, don't call me about any weddings, by the way. But anything else, it's fine. That's good. So I think we've covered everything except, you know, Chris. So Chris, I want to give you the last word. You're on mute, Chris. Because he probably has two, three monitors. You know, a lot's been said, I appreciate Bill's comments and also Sam. I mean, I think I would agree that Stelios said, I think this was the best one yet. And despite the fact that you had so many difficulties through the year and we talked a number of times too and our deepest condolences for the loss of your mother and your sister. You know, I think it also came at a really good time because, you know, even the oldest among us have been through a unique life experience the last 18 months. None of us have ever experienced anything like this. And both on a personal level, but also on a professional level because this crisis put healthcare right in the middle of it. It caused everyone to really think about what we have been doing for decades. I think because what we do has so much underlying risk that the actual process of what we do is very conservative. You know, we haven't, you know, why haven't we been doing online, signing up a patients and consenting a patients before? I mean, it made no sense. But, you know, it has always buttoned on this way. We've also been working in silos in a lot of different ways despite some of the collaborative efforts. So it was a great time I think to take stock of saying, you know, we really had to question almost everything that we do and have done on autopilot for many years and try to capitalize on that for the betterment of patients outside of COVID. So I think that was a really good time for us to reflect on that. I thought although the panels had good pace, flowed well, the graphics were great. I would also congratulate you on, we have done a better job of inclusiveness this year. And what struck me is that in so doing, how much tremendous talent that we capture on that way. There's just amazing talent in this industry and that's the real benefit of inclusiveness is that we actually can bring more people from whom we can learn and who bring different thoughts. And, you know, there's always a risk that those of us who've known each other for many years, we think in a particular way, but you know, it's the need for disruption constantly in our business. And I think we need these disruptive forces by constantly having a new flow of talent and bringing new thoughts. So I wanna congratulate you, Karun, for all that, you know, bringing this together despite a challenging year and particularly for Andy. You know, Andy, you're, hopefully you didn't have to travel quite as much to Japan this year, but still, you know, you're sitting on top of a huge machine and you know, we all know too well, the pressures that people like you and John are under in these large, vast corporations and the job never ends and that you find the time to do this. It's not just a time today, but you know, obviously a huge amount of thought has to go into making all of these panels a success. This doesn't just happen by itself. And it's just amazing that you do that. It's a real act of leadership that goes beyond your just your day job. You're really, I couldn't be more proud of you and how you stepped up as a leader in our industry. So congratulations and thank you. Totally agree with you, Stelios, I think, because Andy will again, he's pretty good in giving the, returning the ball. So he's always accessible because I keep telling him the biggest issue is the access because understand people are busy, but you can't chase once, twice, thrice over there. But Andy, if you are to, even on the weekend, like crisis, which will happen, you will always be at a calm and quiet and give you a council over there. And that's where your strength is there that sometimes you take wrong decisions, sometimes you're like really excited about certain things over there, but you can always count on him because he will either text you right to you or call you. He's available. So it's brilliant. But I must tell you something like yesterday night, it was with Stelios, we are exchanging because I want to make sure that like his chat with Pfizer, his dear friend, Albert goes well because like Chris, you said about the corporation. So the big corporation, have this communication colleagues and their VP of corporate affairs and regularity affairs. So they are very like, they try to put it, they understand that they have to do their job over there. And so yesterday CNBC in India, like I knew they're managing it for a long time. So she said, oh, we are doing this because right now I think whatever Pfizer is doing or going to do with India is pretty hot. Until date, Albert has not spoken to anybody in India. But of course he's been done by his staff and colleagues and Asia-Pacific heads, what all. So this was very timely. I think the heads off to Stelios is that he made it look so easy as if Albert just walked in here since last September, he has been talking to him. He agreed on that. And he kept his calendar free for today and he was very, very open. So there's a lot of excitement. But yesterday, so this Shrin Bhan, she is the emerging editor of CNBC in India. So she said, we want to cover this. I said, okay, what do you want to cover? He said, no, we want to do this Albert Blas chat. I said, the man who's doing it is Stelios. So he said, yes, so we want to bring it live. Do it live. I said, okay, you do it. So I just emailed Stelios that they want to do it live. He says, wonderful, go for that. I said, okay, I told her, he's very happy. You can do that. And she was so happy. And then Stelios said, you wanted to announce it. Like it didn't mean that with marketing point of view. So I said, Stelios said, should he announce it? So she was all over. So what they did today, I'm looking at all the tweets which are there on CNBC in India. I didn't even know what they did, but they got the direct feed from our streaming partners. Because as if it was their feed, which is coming in, it's exclusive, they got it. It's called CNBC exclusive with Albert Blas. But it's got it. And every media house, the newspapers, like whatever he said, I think if you Google it today, you'll find out it's on fire. Like, I told the joking day to Stelios that your fireside actually is on fire. All over India is the first time Stelios spoke. And there's a hope. And I can tell you like, ideas that they're feeling that in this second COVID wave, it was pretty brutal. And the next wave, they think it could be harming the children disproportionately. And the only vaccine which is there available is trial is Pfizer vaccine. So there's a hope that whatever this year, next year, they need that otherwise they will be in big trouble. So Stelios, thanks a lot for getting it done. It is not just getting a CEO of a Pfizer, but it was very timely. Because when we discussed last year, within September was not a time we thought it will be in this situation in COVID with the second wave. But it was great. He came, he was very eloquent and he really meant like in the public domain, whatever he could share. So I think that for me was a big take. And of course, the biggest thing was what Andy did. So smooth, very quietly did everything. And I know, so thank you so much. I know it's about 430 raining in Boston in the North Shore. So I could hear the rain over there. So I know you're all in different locations. Enjoy it. We will definitely try to meet. We are hopefully we are all vaccinated and understand. So maybe in November, December, we'll do our private small dinner, start with that thing should be okay. And we'll keep the dialogue on. But thanks a lot, really appreciate the good work, the critical work all of you are doing. See you soon, all of you, really appreciate. Bless you, have all of you. Thank you. Thank you, Ter. Bye, everyone. Bye. Thank you.